Inmagene Biopharmaceuticals’ drug candidate, IMG-004, secured clearance from the US Food and Drug Administration (FDA) to be investigated in a Phase I clinical trial.

A reversible, non-covalent, third-generation small molecule inhibitor of Bruton Tyrosine Kinase (BTK), IMG-004 is being developed for the potential treatment of immunological diseases. IMG-004 was discovered by Hutchmed, while Inmagene obtained the rights to develop it at the candidate stage.

It is a selective and brain permeable drug intended for inflammatory and autoimmune ailments that need long-term treatment.

A non-receptor intracytoplasmic tyrosine kinase, BTK belongs to the Tec family of protein tyrosine kinases. It is involved in innate as well as adaptive immune responses linked to various immune-mediated ailments. 

Due to BTK’s key role in immunity pathways, BTK inhibitors could provide a potential treatment approach for treating various inflammatory and autoimmune diseases.

The double-blind, placebo-controlled, randomised, single and multiple dose escalation trial will enrol healthy participants.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Analysing the safety, tolerability, pharmacokinetics and pharmacodynamics of IMG-004 in healthy participants is the goal of the trial.

Inmagene Biopharmaceuticals chief development officer Dr Jean-Louis Saillot said: “BTK inhibition is an attractive target for a variety of inflammatory and autoimmune diseases, based on demonstrated activity or its current evaluation in clinical trials.

“IMG-004’s improved activity, selectivity, and pharmacokinetic profile in preclinical studies compared to those of other BTK inhibitors point toward a best-in-class potential.”

A clinical-stage biotechnology company, Inmagene develops new therapies to treat immunology-linked diseases.

It is building a pipeline of approximately 20 drug development programmes.